Ubidecarenone is under clinical development by BPGbio and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ubidecarenone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ubidecarenone is under development for metastatic pancreatic adenocarcinoma, breast cancer, refractory solid tumor, brain cancer, lymphoma, epidermolysis bullosa, recurrent high-grade glioma, anaplastic astrocytoma, gliosarcoma, and glioblastoma multiforme. The drug candidate is administered through topical and intravenous infusion routes. Ubidecarenone is a naturally occurring coenzyme structurally similar to vitamin K. The drug candidate is developed by NAi interrogative biology platform (AI driven platform).
It was also under development for the treatment of liver cancer, lupus, wounds, skin cancer, chemotherapy effects, leukemia, basal cell carcinoma and third line therapy of gastric cancer, colon cancer, kidney cancer (renal cell cancer), head and neck cancer, non-small cell lung cancer, malignant mesothelioma, bladder cancer, cutaneous squamous cell carcinoma and sarcopenia.
BPGbio is a clinical-stage biopharma company which uses AI to detect the risk of drug discovery for humanity. BPGbio is headquartered in Framingham, Massachusetts, the US.
For a complete picture of Ubidecarenone’s drug-specific PTSR and LoA scores, buy the report here.